Eylward Susan sold $2K of IMNN

Eylward Susan (General Counsel and Corp Sec) sold 920 shares of Imunon, Inc. (IMNN) at $1.88 on 2026-07-06.

Original reporting
SEC EDGAR · Eylward Susan
Published Jul 7, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IMNN
Neutral
low confidence
Mentioned
$IMNN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

This provides a fresh datapoint on insider selling activity, but it does not include earnings, guidance, clinical, regulatory, or deal information that would change valuation drivers.

02

Market read

Traders may monitor IMNN for follow-on insider activity, but the filing alone is unlikely to drive a major repricing.

03

What to watch

The absence of a 10b5-1 plan can raise attention, but the article provides no context on motivations, taxes, or prior planned sales.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-07, transaction dated 2026-07-06

Background

The article is a SEC Form 4 insider transaction disclosure for Imunon, Inc. (IMNN).

Company-level read

Ticker impact

$IMNNNeutralLow confidence
Context

Imunon disclosed an insider open-market sale by General Counsel Susan Eylward of 920 shares at $1.88 on 2026-07-06.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless accompanied by other disclosures.

Evidence & confidence

Form 4 insider sales are common and this transaction is small relative to typical market moves, with no 10b5-1 plan and no accompanying fundamental catalyst in the text.

Market effects

No sector-wide implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification or personal liquidity needs and does not necessarily reflect a negative view of the business.

Key entities

  • Imunon, Inc.

    Subject of the Form 4 insider sale disclosure (IMNN).

  • Eylward Susan

    General Counsel and Corp Sec who sold 920 shares at $1.88 on 2026-07-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.